Qualigen Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
AIxCrypto Holdings, Inc. has filed an S-1 registration statement to allow for the resale of up to 55 million shares of common stock by a selling stockholder, potentially raising up to $50 million through a volume-weighted average price (VWAP) purchase agreement.
AIxCrypto Holdings, Inc. files S-1 for the resale of 18.1 million common shares by selling stockholders, signaling a strategic shift to cryptocurrency treasury operations and addressing Nasdaq compliance.
Qualigen Therapeutics files S-1 to register up to 3.2 million common shares for resale by existing Series A-3 Preferred stockholders, with no proceeds going to the company.
S-1: Qualigen Therapeutics Files for Resale of 3.4 Million Shares Following Preferred Stock Conversion
Qualigen Therapeutics is registering for resale up to 3,436,281 shares of common stock issuable upon conversion of Series A-2 Preferred Stock held by selling stockholders.
Qualigen Therapeutics aims to raise up to $1.8 million through a public offering of common stock and pre-funded warrants to fund operations, marketing, and potential acquisitions.
Qualigen Therapeutics aims to raise up to $4 million through a public offering of common stock and pre-funded warrants to advance its clinical programs and for general corporate purposes.
S-1/A: Qualigen Therapeutics Eyes $4 Million Raise Through Common Stock and Pre-Funded Warrants Offering
Qualigen Therapeutics aims to raise up to $4 million through a public offering of common stock and pre-funded warrants to advance clinical trials and for general corporate purposes.
Qualigen Therapeutics aims to raise up to $4 million through a public offering of common stock and pre-funded warrants to advance its clinical programs and for general corporate purposes.
Qualigen Therapeutics aims to raise up to $10 million through a best efforts offering of common stock and warrants to fund its QN-302 clinical trial, repay debt, and explore strategic opportunities.